Manager's transactions, Helsinki, 13 December 2016, at 9.00 am
Person subject to the notification requirement
Name: Järnefelt, Gustaf
Position: Other Senior Manager
Issuer Name: Nexstim Oyj
LEI: 743700S7ZI0LNMHZ6Y27
Nature of the notification: INITIAL NOTIFICATION
Reference number: 743700S7ZI0LNMHZ6Y27_20161209153820_3
Transaction date: 9 December 2016
Venue: FIRST NORTH FINLAND (FNFI)
Instrument: SHARE
ISIN: FI4000102678
Nature of the transaction: ACQUISITION
Transaction details
(1): Volume: 10,500 Unit price: 0.16000 EUR
(2): Volume: 36,500 Unit price: 0.17000 EUR
Aggregated transactions
(2): Volume: 47,000 Average price: 0.16777 EUR
NEXSTIM PLC
Martin Jamieson, Chairman and CEO
Further information is available on the website www.nexstim.com or by contacting:
Nexstim +447715163942
Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com
UB Securities Oy (Certified Adviser) +358 (0)9 2538 0246
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan nexstim@consilium-comms.com
About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic neuropathic pain, major depression and stroke therapy. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com